Stay updated with breaking news from Aaront Gerds. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who were not good candidates for the standard treatment of intensive chemotherapy had a median overall survival (OS) of 6.5 years on an alternate regimen of dasatinib and blinatumomab.
/PRNewswire/ -- Researchers report striking progress in the application of cutting-edge tools and treatments to address longstanding challenges in blood...
Aaron T. Gerds, MD, PhD, expands on the potential role of momelotinib in the treatment of patients with myelofibrosis who present with anemia, details the data from MOMENTUM, and explains what FDA approval of momelotinib could mean for the treatment of this patient population.